Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 6:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–8 of 8 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Atrial Septal Defect
Interventions
GORE® CARDIOFORM ASD Occluder
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
Not listed
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 17 more
Conditions
Atrial Septal Defect
Interventions
AMPLATZER Septal Occluder
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
51
States / cities
Birmingham, Alabama • Los Angeles, California • Madera, California + 44 more
Conditions
Left Atrail Appendage Closure: Peri-device Leaks
Interventions
leak closure with either detachable embolization coils, vascular plugs/CSO, or RFA
Other
Lead sponsor
Kansas City Heart Rhythm Research Foundation
Other
Eligibility
18 Years and older
Enrollment
160 participants
Timeline
2015 – 2021
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Atrial Septal Defect Secundum
Interventions
atrial septal occluder
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
65
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 50 more
Conditions
Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA
Interventions
LAmbre PlusTM Left Atrial Appendage Closure System, Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)
Device · Drug
Lead sponsor
Brian O'Neill MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Septal Defect, Atrial
Interventions
GORE® CARDIOFORM Septal Occluder
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Heart Septal Defect, Heart Septal Defects, Atrial, Heart Defects, Congenital, Cardiovascular Abnormalities, Cardiovascular Diseases, Heart Diseases, Congenital Abnormalities
Interventions
reSept ASD Occluder
Device
Lead sponsor
atHeart Medical
Industry
Eligibility
Up to 84 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Thousand Oaks, California + 21 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Long-term Safety Study of the GORE® HELEX® Septal Occluder

NCT00581308
Conditions
Septal Defect, Atrial
Interventions
GORE® HELEX® Septal Occluder
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
Not listed
Enrollment
215 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio